Holy Hormones Journal: Merck, hmm… now where have I heard that name before. Oh, yeah the infamous pharmaceutical company that manufactures birth control methods that do not protect against STD’s; markets them to teens and young adult women – and then who stands on the other side of the fence holding their HPV vaccine needle, Gardasil waiting to inoculate their unsuspecting new market of girls.
Now that the murky Merck connection is established let’s move on to this press announcement. What is NuvaRing?
NuvaRing is the trade name for a combined hormonal contraceptive vaginal ring manufactured by Merck (formerly Schering-Plough, formerly Organon) that is available by prescription. It is a flexible plastic (ethylene-vinyl acetate copolymer) ring that releases a low dose of a progestin and estrogen over three weeks. It is currently used by approximately 1.5 million women worldwide.
A recent study found that users of vaginal rings with ethinyl estradiol and etonogestrel have a 6.5 times increased risk of venous thrombosis compared to non-users. This is commensurate to the risk of thrombosis due to the use of combined oral contraceptive pills, which in studies ranged between 2.9 times to 13.7 times the risk. Wikipedia
One, other thing NuvaRing should not be used while breastfeeding. The synthetic hormones pass to the baby through the mother’s milk, and decreasing milk production.
Find Out What The Oh! Is All About (Merck’s Marketing Gimmick)
So – a drug is fast-tracked through the FDA – put on the market… marketing dollars spent to advertise the product to unsuspecting women ($$), lawsuits filed ($$), legal fees paid ($$), medical costs paid ($$) – and women are still left with what? How many times are we going to let ourselves be medical experiments?
Just one other comment. What kind of drug manufacturer with a heart and concern for the consumers they market to would put a clause in the lawsuit that ‘ they had a RIGHT to abandon the deal unless 95% (3,800) eligible claimants opted in’? Really? My suggestion is that if a product has Merck on the label – turn and walk away.
A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement, those involved in the lawsuits said Thursday.
U.S. District Judge Rodney W. Sippel of St. Louis approved the settlement in February, but NuvaRing maker Merck & Co. had the right to abandon the deal if less than 95 percent of eligible claimants opted in.
The lead attorney for the claimants, St. Louis lawyer Roger Denton, said the 95 percent threshold has been reached, and the deal is now final. Merck, in a statement, confirmed that the agreement is final.
Denton said about 3,800 claimants will share in the settlement.
NuvaRing is a hormonal contraceptive inside a flexible ring that slowly releases two hormones into the vaginal wall: ethinyl estradiol, a type of estrogen that is widely used in contraceptives, and a progestin called etonogestrel. Merck has been selling NuvaRing since 2002.